Data Sheet (Cat.No.T67960)

TargetMol

Recainam

Chemical Properties



CAS No. : 74738-24-2

Formula: C15H25N3O

Molecular Weight: 263.38

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Recainam is a novel, orally available compound with potent class I antiarrhythmic activity.
Targets(IC50)	Others
In vivo	Recainam was administered at a loading dose of 4.5 mg/kg/hour over 40 minutes, followed by a maintenance infusion of 0.9 mg/kg/hour for 23 hours and 20 minutes. The mean frequency of total VPCs decreased by 92.6% and the mean frequency of runs decreased by 99.9% during the maintenance infusion. Suppressions of > or = 70% of total VPCs and > or = 90% of runs were maintained over the 23-hour, 20-minute maintenance infusion period in 16 of the 18 patients. During the maintenance infusion, hourly group plasma Recainam concentrations ranged from mean +/- SD 2.6 +/- 0.7 to 3.4 +/- 0.9 micrograms/ml. The following pharmacokinetic parameters were obtained: terminal elimination half-life, 5.0 +/- 0.8 hours; systemic clearance, 0.27 +/- 0.08 liter/hour/kg; and central and steady-state volume of distribution, 0.32 +/- 0.11 and 1.4 +/- 0.4 liter/kg, respectively.[2]

Solubility Information

Solubility	DMSO: 45 mg/mL (170.86 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.7968 mL	18.984 mL	37.968 mL
5 mM	0.7594 mL	3.7968 mL	7.5936 mL
10 mM	0.3797 mL	1.8984 mL	3.7968 mL
50 mM	0.0759 mL	0.3797 mL	0.7594 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Scatina JA, et al. Species differences in the pharmacokinetics of recainam, a new anti-arrhythmic drug. Biopharm Drug Dispos. 1990;11(5):445-461.

Anderson JL, et al. Antiarrhythmic and pharmacokinetic evaluation of intravenous recainam in patients with frequent ventricular premature complexes and unsustained ventricular tachycardia. Am J Cardiol. 1993;71(8):686-694.

Colatsky TJ, et al. Cellular electrophysiology of the new antiarrhythmic agent recainam (Wy-42,362) in canine cardiac Purkinje fibers. J Cardiovasc Pharmacol. 1987;9(4):435-444.

Tai YT, et al. Electrophysiologic effects and antiarrhythmic efficacy of recainam in patients with supraventricular tachycardia. J Cardiovasc Pharmacol. 1991;17(2):310-315.